On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Executives from ChineseInvestors.com Inc.’s (CIIX) CBD Biotech Subsidiary Network and Share Product Offerings at Major Conferences

  • CIIX has carved out unique niche in Chinese-speaking markets, is applying similar business model to rapidly growing CBD industry
  • Focused on China’s emerging industrial hemp and CBD market, which is predicted to reach over $20 billion by 2022
  • Meeting with companies, executives, and investors at conferences in Shanghai and Haerbing, China

ChineseInvestors.com Inc. (OTCQB: CIIX) is a leading financial news platform for the global Chinese-speaking community. The company offers real-time financial information in Chinese language character sets. By concentrating on the Chinese-speaking markets, CIIX has carved out its own unique niche. This same business model is being applied to the burgeoning cannabidiol (CBD)-based nutrition and health industry.

Early on, CIIX recognized opportunities in the U.S. cannabis industry and began laying groundwork to capitalize on the demand for quality CBD products in the Chinese-speaking community. The wholly owned subsidiary CBD Biotech Inc. was created to allow CIIX to focus on investor education products and services. The company has already established itself with the first Chinese-language CBD store online, a CBD pop-up kiosk in Glendale Galleria Mall in California, and the launch of its rebranded CBD consumer product line. Now, CBD Biotech is reaching out beyond the U.S. and is focused in on China’s emerging market, predicted to reach over $20 billion by 2022. CIIX’s CEO Warren Wang has stated that the company hopes for a Nasdaq IPO of CBD Biotech late in FY2019 or early 2020 (http://ibn.fm/bw6Q9). The company’s goal is to become the leading Chinese CBD public trading company.

Recently, the 2019 China Industrial Cannabis Investment Seminar was held in Shanghai, bringing together a myriad of companies and individuals interested in the industrial hemp market. The conference took place October 31, 2019 and was attended by CBD Biotech executives who are now gearing up to attend the 2019 China Industrial Cannabis CBD Industry International Conference in Haerbing, slated for November 23-24, 2019. Both conferences enable CBD Biotech executives to share information and education on the company’s industrial hemp-infused skincare and cosmetic products, showcase its hemp wine, feature new products soon to launch, and discuss strategic plans for future development.

As one of the first movers in this market, CBD Biotech will meet with companies and executives in China who are also active or are considering entry into the industrial hemp market. There is also ample opportunity to network with foreign industrial hemp companies, institutional investors, secondary market institutional investors, and other high net worth investors who are interested in the industrial hemp market in China. Currently, in China, there is a potential market for hemp-infused/CBD skincare and cosmetics of nearly 1.4 billion people. ChineseInvestors.com, through its subsidiary CBD Biotech, is well positioned to take advantage of this market.

To discover more about the company’s involvement in these conferences, visit http://ibn.fm/ks9m2

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection

December 12, 2019

POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer The power of artificial intelligence (AI) to […]

Rotate your device 90° to view site.